During Tuesday’s Current trade, Shares of Newpark Resources Inc (NYSE:NR), gain 2.40% to $7.24.
Newpark Resources, Inc. (NR) declared results for its second quarter ended June 30, 2015. Total revenues for the second quarter of 2015 were $163.6 million contrast to $208.5 million in the first quarter and $272.5 million in the second quarter of 2014. Net loss for the second quarter of 2015 was $4.3 million, or $0.05 per share, contrast to net income of $1.0 million, or $0.01 per diluted share, in the first quarter, and $20.3 million, or $0.21 per diluted share, in the second quarter of 2014.
Second quarter 2015 results comprised of a $1.7 million ($0.02 per share) charge to provision for income taxes to impair formerly-recorded deferred tax assets in Australia.
Newpark Resources, Inc. provides various products and services primarily to the oil and gas exploration industry. The company operates in two segments, Fluids Systems, and Mats and Integrated Services. The Fluids Systems segment provides drilling fluids products and technical services for technical drilling projects involving complex subsurface conditions, such as horizontal directional, geologically deep, or deep water drilling.
Shares of Bunge Ltd (NYSE:BG), inclined 0.51% to $80.22, during its current trading session.
Bunge Limited (BG) Reports Second Quarter 2015 Results.
- Total adjusted segment EBIT of $152 million, down $266 million vs. last year
- Agribusiness lower due to weak softseed processing and trading & distribution results
- Food & Ingredients influenced by market slowdown in Brazil
- YTD total adjusted segment EBIT of $525 million, up $32 million vs. last year
- Combined Agri-Foods rolling 4Q ROIC of 9.6%; 2.6 points over WACC
- Expect strong 2H in Agribusiness, improvement from 1H in Foods and combined full year Agri-Foods ROIC of ~10%
Overview
Soren Schroder, Bunge’s Chief Executive Officer, stated, “Conditions in the second quarter were more challenging than predictable. In Agribusiness, we practiced weak softseed margins, slow farmer selling outside of Brazil and a difficult trading & distribution environment. In Food & Ingredients, margins and volumes came under dramatic pressure in our Brazilian businesses, especially Edible Oils, as consumers adjusted to an environment of increasing unemployment, inflation and currency devaluation.
Bunge Limited, through its auxiliaries, operates as an agribusiness and food company worldwide. It operates in five segments: Agribusiness, Edible Oil Products, Milling Products, Sugar and Bioenergy, and Fertilizer. The Agribusiness segment engages in the purchase, storage, transport, processing, and sale of agricultural commodities and commodity products, such as oilseeds and grains, counting soybeans, rapeseed, canola, sunflower seeds, wheat, and corn to animal feed manufacturers, livestock producers, wheat and corn millers, other oilseed processors, third-party edible oil processing companies, and biodiesel industries. T
Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS), during its Tuesday’s current trading session gained 0.01% to $1.37.
Sunesis Pharmaceuticals, Inc. (SNSS) stated financial results for the second quarter ended June 30, 2015. Loss from operations for the three and six months ended June 30, 2015 was $10.6 million and $19.4 million, respectively. As of June 30, 2015, cash, cash equivalents and marketable securities totaled $39.6 million.
Second Quarter 2015 Highlights
- Received European regulatory guidance regarding potential marketing authorization application for Vosaroxin in AML. In July 2015, Sunesis declared that, following pre-submission advisory meetings to talk about the potential submission of a Marketing Authorization Application (MAA) for vosaroxin in Europe, the company is proceeding with an MAA filing. The MAA will focus on the indication of relapsed/refractory acute myeloid leukemia (AML) in patients age 60 years and older, a population with the greatest medical need and for whom the greatest benefit was observed in the vosaroxin/cytarabine treatment arm of VALOR, the company’s pivotal Phase 3 study of vosaroxin in adult patients with relapsed or refractory AML.
- Received feedback from FDA regarding NDA filing for Vosaroxin in AML. In July 2015, Sunesis declared that, following a recent meeting with the U.S. Food and Drug Administration (FDA), the FDA recommended that the company provide additional clinical evidence to support a future NDA submission. The company is presently evaluating and refining its plan to gain marketing approval in the U.S. based on this feedback.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has accomplished a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.
Finally, Scientific Games Corp (NASDAQ:SGMS), decreased -10.82%, to $13.42.
Scientific Games Corporation (SGMS) stated results for the second quarter ended June 30, 2015.
The Company also recorded the following $9.2 million of aggregate charges in the 2015 second quarter that are not in the table above nor comprised of as add-backs to AEBITDA:
- An incremental charge of $2.7 million for bad debt expense related to recent customer bankruptcies;
- Incremental inventory write-downs of $1.2 million due to excess and obsolete inventory;
- Legal costs of $2.0 million associated with legal settlements; and
- Accrual of $3.3 million related to Northstar Lottery Group, LLC (“Northstar Illinois”), which has signed a term sheet with the State of Illinois to settle their dispute regarding the termination of a private administration agreement. Scientific Games recorded its share of the projected settlement, of which $2.0 million was recorded as a reduction of earnings from equity investments and $1.3 million as a reduction in instant games revenue. The parties are negotiating a final settlement agreement based on the term sheet.
Scientific Games Corporation develops technology-based products and services, and associated content for the gaming and lottery industries worldwide. The company operates through three segments: Gaming, Lottery, and Interactive. The Gaming segment offers gaming machines, conversion kits, automatic card shufflers, roulette chip sorters, and spare parts; leases gaming machines, automatic card shufflers, roulette chip sorters, and server-based gaming systems and content; and licenses proprietary table game content. This segment also provides video lottery central monitoring and control systems and netoperates for gaming regulators; and casino-administration technology solutions and systems. This segment serves commercial, tribal, and governmental gaming operators.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
